Exelixis' CELESTIAL Liver Trial Succeeds, But Can Cabozantinib Compete?
CELESTIAL second-line liver cancer study is positive, but 4% response rate pales in comparison to PD-1 performance of Bristol's Opdivo and Merck's Keytruda.
CELESTIAL second-line liver cancer study is positive, but 4% response rate pales in comparison to PD-1 performance of Bristol's Opdivo and Merck's Keytruda.